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Abstract
Background: The ovulatory surge of gonadotropins triggers oocyte maturation and rupture of
the ovarian follicle. The resumption of nuclear maturation in the oocyte from the prophase stage
is characterized by germinal vesicle breakdown (GVBD). It has previously been shown that specific
inhibition of cAMP degradation by PDE3 prevents the resumption of oocyte meiosis. However, no
report has characterized the activity of PDE3 in the porcine oocyte, or the implication of the cAMP-
PDE3 pathway in the entire nuclear maturation process. In this study, PDE3 activity in the oocyte
was assessed during in vitro maturation (IVM) and the possible roles of the cAMP-PDE3 pathway in
the resumption and progression of meiosis were investigated in terms of different models of oocyte
maturation.
Results: Cyclic AMP-degrading PDE activity was detected in the cumulus-oocyte complex (COC)
and was partially inhibited by a specific PDE3 inhibitor, cilostamide. When measured only in the
denuded oocyte, PDE activity was almost completely inhibited by cilostamide, suggesting that
cAMP-PDE3 activity is the major cAMP-PDE in porcine oocytes. PDE3A mRNA was detected by
RT-PCR. PDE3 activity did not vary significantly during the early hours of IVM, but a maximum was
observed at 13 hours. In cumulus-oocyte complexes, meiosis resumed after 20.81 hours of culture.
PDE3 inhibition no longer maintained meiotic arrest if sustained beyond 17.65 hours of IVM, 3
hours prior to resumption of meiosis. Thereafter, PDE3 inhibition progressively lost its efficacy in
GVBD. When the protein phosphatase 1 and 2A inhibitor okadaic acid was continuously or
transiently (3 hours) present during IVM, meiosis resumed prematurely; PDE3 inhibition was unable
to prevent GVBD. However, PDE3 inhibition in COC treated with OA for 3 hours significantly
delayed meiosis at the intermediate stage.
Conclusion:  The present investigation has demonstrated that PDE3A is the major cAMP-
degrading PDE in the oocyte. It regulates the resumption of meiosis until 3 hours prior to GVBD
and transiently affects meiotic progression.
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Background
Oogonia entering meiosis progress to the diplotene stage
of the first meiotic prophase, at which they display a char-
acteristic nucleus commonly known as the germinal vesi-
cle (GV). Oocytes arrested at the GV stage, prophase I of
meiosis, enter a growth phase during which the follicle
differentiates from the primary to the preovulatory stage.
Oocytes acquire the capacity to resume meiosis during
this period and rely on 3'5'-cyclic adenosine monophos-
phate (cAMP) to prevent premature resumption. Cyclic
AMP is produced in the somatic granulosa cells and trans-
ferred through gap-junction channels [1]. Recent findings
have shown that cAMP-producing capacity is also impor-
tant in maintaining the prophase I-arrested state in
oocytes [2]. Cyclic AMP activates the cAMP-dependent
protein kinase (PKA) by binding to the two regulatory
subunits, liberating the two active catalytic subunits. High
concentrations of cAMP and correspondingly high PKA
activity within the oocyte prevent the resumption of mei-
osis, as shown using cAMP analogues [3,4], adenylyl
cyclase activators [5,6] and invasive adenylyl cyclase treat-
ments [7]. Microinjection of Xenopus oocytes with the
catalytic subunit of PKA also maintains them in the GV
stage [8]. However, the PKA-mediated mechanism that
maintains meiotic arrest is not fully understood, although
interesting advances have recently been made on possible
PKA targets in mouse oocytes, such as CDC25B phos-
phatase and Wee1B kinase, two cell cycle regulators [9].
Cyclic AMP is degraded by members of the phosphodi-
esterase (PDE) family [10]. PDEs are important regulators
of ovarian physiology. During the past few years, PDE3
family-specific inhibitors (e.g. cilostamide, milrinone,
Org 9935) have been shown to block the resumption of
meiosis efficiently in murine [11], rat [12], bovine
[13,14], porcine [15,16], macaque [17] and human [18]
oocytes. PDE3A- and PDE4D-null female mice respec-
tively show infertility and impaired fertility [19,20]. Inter-
estingly, PDE3A-deficient mice ovulate fully-grown
oocytes, but they fail to resume meiosis [20]. In rat
oocytes, a cAMP-degrading activity sensitive to cilosta-
mide (PDE3-specific) is increased 2-fold prior to resump-
tion of meiosis, strongly suggesting that cAMP
degradation is actively regulated in the oocyte and that
regulation of PDE3A is part of the mechanism controlling
resumption of meiosis [21].
Nuclear maturation in the oocyte and rupture of the folli-
cle are triggered by an ovulatory surge of gonadotropins in
vivo. The latter is characterized by breakdown of the germi-
nal vesicle (GVBD). GVBD is correlated with an increased
activity of M phase-promoting factor (MPF). MPF is essen-
tial for GVBD, chromosome condensation, formation of
microtubules around the condensed chromosomes and
their organization into a bipolar structure [22]. The com-
plete molecular pathways linking the endocrine cues to
the first activation of MPF in the oocyte during nuclear
maturation are unclear. However, it is known that gona-
dotropins trigger multiple phosphorylation cascades and
second messenger signalling pathways in the somatic
compartment of the ovarian follicle, and these are critical
for the correct timing of oocyte maturation. Simultane-
ously with activation of the MPF, mitogen-activated pro-
tein kinase (MAPK) activates phosphorylation in the
oocyte and is believed to be implicated in chromosome
condensation and microtubule organisation [23]. After its
initial increase, MPF activity stays high until metaphase I
before decreasing prior to homologous chromosome seg-
regation and extrusion of the first polar body [22]. A sec-
ond increase in MPF activity maintains metaphase II prior
to sperm penetration. Although this second activation is
known to depend on factors such as cyclin B synthesis,
presence of the nucleus and MAPK activity, the precise
implication of the PDE3A/cAMP/PKA pathway remains
unknown [22,24]. Our laboratory has recently described
physiological evidence showing the pivotal role of cAMP
and its modulation by PDE3 in regulating the resumption
of meiosis in porcine oocytes [15]. Since no study has
reported the progression of PDE3 activity during porcine
oocyte nuclear maturation, the goal of the present study
was to measure PDE3 activity in the oocyte during in vitro
maturation (IVM) and to characterize the effect of PDE3
inhibition on different steps of nuclear maturation.
Results
Contributions of different cAMP-degrading PDEs in the 
oocyte
The PDE assay was optimized for porcine COC. Increasing
numbers of COC were used to measure cAMP hydrolysis.
The hydrolytic activity was linearly related to the number
of COC and 10 COC or denuded oocytes were used (data
not shown). In experiment 1, cAMP-degrading PDE3
activity was measured in cumulus-oocyte complexes
(COC) after recovery from the ovary with or without PDE
inhibitors. The total cAMP-PDE activity in porcine COC
was 10.98 ± 0.99 fmol cAMP degraded/min/COC, and
this activity was decreased by non-specific and family-spe-
cific PDE inhibitors. Figure 1A shows that 66% of the
cAMP-degrading PDE activity is inhibited by the non-spe-
cific inhibitor 3-isobutyl-methylxanthine (IBMX), while
19% and 7% inhibition are achieved, respectively, by
PDE3-specific (cilostamide) and PDE4-specific (rol-
ipram) inhibitors (figure 1A). IBMX inhibits every cAMP-
PDE subtype except for PDE8. The IBMX-sensitive (PDE1,
3, 4, 7, 10 and 11), cilostamide-sensitive (PDE3) and rol-
ipram-sensitive (PDE4) activities were calculated as
described in the experimental design section and reported
in figure 1B. The cAMP-degrading PDE activity in the
oocyte was 2.57 ± 0.57 fmol cAMP degraded/min/oocyte
(figure 1C). Cyclic AMP-PDE3 activity measured in theBMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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denuded oocyte was almost equivalent to the total activ-
ity. Moreover, these two activities are similar to the cAMP-
PDE3 specific activity measured in COC (figure 1C), sug-
gesting that PDE3 is the predominant PDE isoform in por-
cine oocytes. PDE3A mRNA was detected in the oocyte by
RT-PCR (figure 1D). To confirm the identity of the ampli-
fication products further, they were sequenced and found
to be 98.3%, 89.7%, 81.4% and 80.9% identical to pub-
Cyclic AMP-degrading PDE activity in the oocyte Figure 1
Cyclic AMP-degrading PDE activity in the oocyte. A. Cyclic AMP-PDE activity was measured in the COC either alone 
or in the presence of a non-specific PDE inhibitor (IBMX, 1 mM) or of PDE3 (cilostamide, 10 μM) or PDE4 (rolipram, 10 μM) 
specific inhibitors. B. Total and calculated IBMX-sensitive, cilostamide-sensitive (PDE3) and rolipram-sensitive (PDE4) PDE 
activities in the COC are presented. To determine the inhibitor-sensitive contributions to the overall PDE activity, the activity 
measured in the presence of the respective inhibitors was subtracted from the total PDE activity. C. Comparison of the total 
(hatched bars) and cilostamide-sensitive (PDE3) (closed bars) PDE activities in the COC or DO after recovery from the ovary. 
A total of 1290 oocytes were used. Each column represents the mean ± SEM of at least three replicates. D. Reverse transcrip-
tion-PCR analysis of β-actin and PDE3A mRNA in porcine oocyte cDNA. Ethidium bromide-stained 1% agarose gels were used 
to resolve the amplified products. DO: denuded oocyte cDNA; +ve: positive control; -ve: negative control without cDNA. A 
PDE3A amplicon in the oocytes was sequenced and found to have 98.3% identity with the published sequence. Representative 
pictures of the three different experiments are shown.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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lished porcine, human, mouse and rat sequences, respec-
tively.
In experiment 2, oocytes were cultured as COC. At the end
of the culture, the cumulus cells were removed by gentle
pipetting and after several washes the oocytes were
assessed for cAMP-degrading activity. PDE3 activity in the
oocyte was measured at different time points during IVM.
No statistically significant effect of either total, IBMX-sen-
sitive or cilostamide-sensitive (PDE3) phosphodiesterase
activities was observed during IVM (figure 2). However,
maximum PDE activity was measured at 13 hours of IVM,
after which the activity returned to basal level.
Time-dependent ability of specific PDE3 inhibition to 
maintain COC in meiotic arrest
The efficacy of the PDE3 inhibitor, cilostamide, in con-
trolling GVBD was tested. In the previous experiments,
specific PDE3 inhibitors were added at the beginning of
IVM [15,16]. In experiment 3, the addition of cilostamide
was postponed for several hours after the beginning of
IVM. The inhibitor was still efficient at controlling GVBD
when added after 13 and 15 hours of IVM (figure 3A).
When PDE3 inhibition with cilostamide was still further
delayed there was a gradual decrease in its control of
GVBD (figure 3A). A linear regression calculation showed
that 50% of the COC remain in GV when PDE3 is inhib-
ited at 17.65 hours, which is approximately 3 hours prior
to GVBD (figure 3B) and 5 hours after the peak of PDE
activity in the oocyte (figure 2C). As shown in figure 3B,
most of the oocytes resumed meiosis normally under our
culture conditions within a narrow window of 4 hours
between 19 and 23 hours of IVM (regression analysis,
20.81 hours of IVM for 50% GVBD). This result suggests
that the cAMP-PDE3 pathway actively controls mainte-
nance of the GV stage during at least the first 15 hours of
IVM. After 19 hours of cilostamide-free culture condi-
tions, the addition of cilostamide for the last 4 hours had
no significant effect on maintaining the oocytes in the GV
stage (figure 3A). In addition, maximum PDE3 activity
occurs at approximately 13 hours of IVM (figure 2), which
is 6 hours prior to the end of period in which PDE3 inhi-
bition can prevent GVBD. At 19 hours, cAMP-PDE3 activ-
ity is minimal (figure 2C), consistent with its inefficacy in
controlling GVBD.
MPF activation is critical for the resumption of oocyte
meiosis. As proposed above, the period preceding GVBD
is cAMP-PDE3-sensitive. Since MPF activity during IVM in
vertebrate oocytes changes biphasically before reaching
the second meiotic arrest in metaphase II, experiment 4
was designed to verify whether the second MPF activation
depends on cAMP-PDE3 activity. PDE3 was inhibited
with cilostamide after 19 hours of IVM and meiotic matu-
ration was assessed immediately and at 24, 30, 36 and 48
hours afterwards. Of the cilostamide-treated COC, 66.5%
resumed meiosis during 19 and 24 hours of IVM (the
cilostamide-insensitive group) while 33.5% remained in
GV arrest (the cilostamide-sensitive group; figure 4A). The
cilostamide-insensitive oocytes reached an intermediate
nuclear stage at 24 hours (figure 4B). Of this group, 40%
reached the mature nuclear stage at 30 hours, equivalent
to the control oocytes (figure 4C). This result suggests that
oocytes that resume meiosis despite PDE3 inhibition, the
cilostamide-insensitive group, reach the mature nuclear
stage at a similar rate to their control counterparts and
therefore are not affected by PDE3 inhibition. The signifi-
cantly higher percentages of oocytes in GV arrest at 24 (P
< 0.05) and 30 (P < 0.001) hours compared to control
oocytes reveal that cilostamide treatment transiently
maintained the cilostamide-sensitive oocytes in meiotic
arrest (figure 4A). The significantly lower percentage of
oocytes at an intermediate nuclear stage at 24 (P < 0.01)
and 30 (P < 0.001) hours is the result of the delay in mei-
otic resumption for 30% of the oocytes (figure 4A and
4B). The transition of oocytes from intermediate to
mature stage at 24 and 30 hours is not compromised,
since similar percentages of treated and untreated oocytes
reach the mature stage at 30 hours (figure 4C). The delay
in resumption of meiosis caused by cilostamide treatment
can still be observed at 36 hours in the percentage of
oocytes at the mature nuclear stage (79.9 ± 2.5% vs 94.1 ±
3.6%, cilostamide-treated vs control, figure 4C). However,
oocytes under both treatments have completed meiotic
maturation by 48 hours, showing that the effect of late
PDE3-specific inhibition on resumption and progression
of meiosis is transient and fully reversible. These results
suggest that PDE3 inhibition affects GVBD under normal
IVM conditions, but without affecting the progression of
meiosis after its resumption until metaphase II arrest.
Effects of short OA exposure in the presence of PDE3 
inhibition on oocyte nuclear maturation
The protein phosphatase 1/2A (PP1/2A)-specific inhibitor
okadaic acid (OA) has previously been used to stimulate
chromatin condensation and premature GVBD in verte-
brate oocytes [25]. In experiment 5, oocytes treated con-
tinuously with OA (2 μM) displayed significantly lower
levels of arrest than control oocytes (P < 0.0001) at 6 and
12 hours of IVM (figure 5A). To study the effect of PDE3-
specific inhibition on premature GVBD in OA-treated
oocytes, oocytes were exposed to both cilostamide and
OA for 24 hours of IVM. As reported previously, PDE3
inhibition by cilostamide prevents GVBD under normal
IVM conditions (figure 5B) [15]. However, PDE3 inhibi-
tion no longer prevented GVBD in continuously OA-
exposed oocytes (figure 5B). Even when OA addition was
delayed for 6 hours, PDE3 inhibition did not prevent
GVBD (data not shown). These results clearly suggest thatBMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Cyclic AMP-degrading PDE activity measured in the oocyte during IVM Figure 2
Cyclic AMP-degrading PDE activity measured in the oocyte during IVM. Cyclic AMP-PDE activity was measured in 
isolated denuded oocytes (stripped of cumulus cells) at different time points during COC-cultured IVM. Total (A), IBMX-sensi-
tive (B) and cilostamide-sensitive (C) cAMP-PDE activities measured in the oocyte during COC-cultured IVM. A total of 2100 
oocytes were used. Each activity value represents the mean ± SEM of at least three replicates. Statistical analysis by ANOVA 
showed no significant variation in PDE activities during the IVM period (P > 0.05).BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Time-dependent ability of specific PDE3 inhibitionto maintain COC in meiotic arrest Figure 3
Time-dependent ability of specific PDE3 inhibitionto maintain COC in meiotic arrest. (A) COC were cultured in 
cilostamide-free medium for different times followed by the addition of a PDE3 inhibitor, cilostamide (10 μM), up to 24 hours 
of IVM. Each column represents the mean percentage of GV stage oocyte at 24 hours ± SEM of at least three replicates. The 
number of oocytes per treatment is indicated under each bar. Statistical analysis by ANOVA showed that the treatments had 
significant effects (P < 0.0001). Different letters indicate significant differences (P < 0.05) according to the Bonferroni post hoc 
test. (B) Time-course of resumption of meiosis in porcine COC over 25 hours. Non-linear regression showed that 50% of the 
oocytes had resumed meiosis at 20.8 hours of culture. For each time point, 60 oocytes were used. Each value represents the 
mean percentage of GV stage oocytes ± SEM of at least three replicates.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Effect of specific PDE3 inhibitor, cilostamide, on oocyte maturation Figure 4
Effect of specific PDE3 inhibitor, cilostamide, on oocyte maturation. COC were cultured first in cilostamide-free 
IVM medium for 19 hours followed by the addition of cilostamide (20 μM) for up to 48 hours in culture. Control (--■--) and 
cilostamide-treated (---▲---) experiments show the percentages of oocytes in GV arrest (A), intermediate stage (B) and 
mature stage (C). Values represent the means ± SEM of at least three replicates. A total of 590 oocytes were used. Statistical 
analysis by ANOVA showed that effects of treatments were significant (P = 0.001). Asterisks indicate significant differences 
according to the Bonferroni post hoc test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Effect of specific inhibition of protein phosphatase 1/2A by okadaic acid on oocyte maturation Figure 5
Effect of specific inhibition of protein phosphatase 1/2A by okadaic acid on oocyte maturation. A. COC were cul-
tured in the presence of a protein phosphatase 1/2A inhibitor, okadaic acid (2 μM), for 6 or 12 hours of IVM and nuclear status 
was assessed as described in the Materials and Methods section. Results from COC cultured under control conditions (--■--) 
or treated with okadaic acid (---■---) are presented as the mean percentages of GV stage oocytes ± SEM of at least three rep-
licates. A total of 217 oocytes were used. Statistical analysis by ANOVA showed that the treatments had significant effects (P < 
0.0001). Asterisks indicate significant differences (P < 0.001) from the COC control according to the Bonferroni post hoc test. 
B. COC were cultured in the presence of okadaic acid (2 μM) and the specific PDE3 inhibitor cilostamide (20 μM) for 24 hours 
of IVM and were analysed to assess nuclear status. Results are given as the mean percentages of oocytes in GV arrest (open 
bars), intermediate stage (grey bars) and mature stage (closed bars) ± SEM of at least three replicates. The number of oocytes 
per treatment is indicated under each bar. Statistical analysis by ANOVA showed that the treatments had significant effects (P 
< 0.001). Asterisks indicate significant differences (P < 0.001) from control according to the Bonferroni post hoc test.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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inhibition of PP1/2A with OA affects the GVBD signalling
cascade downstream of cAMP-PDE3A in pig oocytes.
Because continuous OA exposure causes meiotic spindle
assembly defects and disperses the condensed chromo-
some configuration at the intermediate nuclear stage (fig-
ure 6B) instead of the normal metaphase I configuration
(figure 6A) [23], a transient exposure of oocytes to OA was
used in experiment 6. As shown in figure 6A, comparable
intermediate nuclear stages could be observed at 12 hours
in the continuously OA-treated and in the 3 hours OA-
treated oocytes, while in the 1 hour OA-treated group the
oocytes were still at the GV stage, as in the control group.
Moreover, the 3 hours OA-treated group had a minimal
percentage of oocytes with dispersed bivalent chromatin
compared with the group continuously exposed for 12
hours (figure 7A). When assessed after 24 hours of IVM,
the control and one hour OA-treated groups both dis-
played a high percentage of intermediate nuclear matura-
tion stage oocytes (figure 7B). Meiosis did not progress
significantly between 12 and 24 hours of IVM in continu-
ously OA-exposed oocytes and still displayed a high per-
centage at the intermediate nuclear stage with a disperse
chromatin configuration (figure 7B). Oocytes exposed for
3 hours to OA displayed 51.9 ± 6.7% of oocytes in the
mature stage, indicating that they may progress through
the intermediate stage. Considering these results, the next
experiments were undertaken using transient (3 hours)
exposure to OA.
Experiment 7 was designed to determine the effect of
PDE3 inhibition on 3 hours OA-treated oocytes. As with
continuous OA treatment (figure 5B), PDE3 inhibition no
longer prevented GVBD in transiently OA-treated oocytes
(open bars in figure 8). These results also show that COC
treated with OA for 3 hours have a higher percentage of
mature stage oocytes at 24 hours (38.8% vs 1.1% of
mature stage oocytes, OA-treated vs control, figure 8).
PDE3 inhibition in 3 hours OA-treated COC affected mei-
osis by maintaining oocytes at the intermediate nuclear
maturation stage (figure 8). These results suggest that
inhibition of cAMP-PDE3 slows the progression of meio-
sis to the mature stage, consistent with a role in MPF acti-
vation.
In experiment 8, to understand the preceding findings fur-
ther, the nuclear stage was assessed every 12 hours up to
48 hours of IVM after the treatments described above.
PDE3 inhibition of COC caused a significantly higher per-
centage of GV stage oocytes after 24 (P < 0.001), 36 (P <
0.01) and 48 (P < 0.01) hours of IVM than in controls (fig-
ure 9A). It also prevented the increase of intermediate (24
hours) and mature (36 and 48 hours) stage oocytes (fig-
ure 9C, 9E). A transient OA exposure (3 hours) triggered a
rapid loss of GV stage oocytes after 12 hours of IVM (fig-
ure 9A, 9B) and a significantly higher rate of mature stage
oocytes after 24 hours of IVM compared to the control
group (figure 9E, 9F). PDE3 inhibition of 3 hours OA-
treated COC did not affect the decline in GV stage oocyte
percentage after 12 or 24 hours of IVM (figure 9B). Con-
sistent with results in figure 8, PDE3 inhibition of 3 hours
OA-treated oocytes allowed intermediate stage oocytes to
accumulate and the appearance of mature stage oocytes to
be delayed after 24 hours of IVM in comparison to OA-
treated oocytes (figure 9D, 9F). These results suggest that
inhibition of cAMP-PDE3 transiently affects the progres-
sion of meiosis in 3 hours OA-treated oocytes.
Discussion
This study demonstrates that in porcine oocytes, PDE3A is
the major active cAMP-PDE; it efficiently regulates the
resumption of meiosis until 3 hours before GVBD and
transiently affects meiotic progression. Four lines of evi-
dence support this conclusion: (1) cilostamide-sensitive
cAMP-PDE activity in the oocyte represents the main
cAMP-PDE activity; (2) PDE3A mRNA was detected in
oocyte cDNA by RT-PCR; (3) PDE3 inhibition after 15
hours of IVM still prevents the resumption of meiosis; (4)
PDE3 inhibition delays nuclear maturation in OA-treated
oocytes.
Total and cilostamide-sensitive (PDE3) PDE activities in
porcine COC and denuded oocytes freshly recovered from
the ovary (figure 1A and 1B) were about the same as
reported for mouse and rat oocytes [11,21]. Furthermore,
PDE3 is the predominant PDE activity in the oocyte (fig-
ure 1A and 1B), as reported for rodents [11,21]. This result
is also consistent with the presence of PDE3A protein
detected by Western blotting in porcine oocytes [26].
PDE3A messenger RNA was detected in the oocyte by in
situ hybridization in rat and by RT-PCR in mouse and
these findings are consistent with the presence of PDE3A
mRNA in porcine oocyte (figure 1D) [11,27]. The
reported levels of cAMP during IVM range from 2 to 10
fmol [28], whereas the level of cAMP-degrading activity in
denuded porcine oocytes reported in this study is around
2.5 fmol of cAMP degraded per minute per oocyte
throughout IVM (figure 1B and 2). These results suggest
that porcine oocytes replenish their cAMP content approx-
imately every minute. Under our culture conditions,
despite the maximum at 13 hours, total and cilostamide-
sensitive (PDE3) phosphodiesterase activities were not
statistically different during IVM (figure 2). One explana-
tion could be that the timing of GVBD is regulated by
multiple cAMP-generating mechanisms. The modulation
of cAMP level in the oocyte involves both the permeability
of the gap-junctions and adenylyl cyclase activity [1,29].
In addition, the present results do not exclude a possible
modulation of PDE3A activity by phosphorylation, which
would be difficult to measure because highly synchro-BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Effects of protein phosphatase 1/2A inhibition on oocyte chromatin condensation Figure 6
Effects of protein phosphatase 1/2A inhibition on oocyte chromatin condensation. (A) Photograph of an oocyte 
stained with aceto-orcein displaying the metaphase I chromatin configuration after 24 hours of IVM. (B) OA-treated oocyte (2 
μM) after 24 hours of IVM displaying condensed bivalent chromatin that is scattered in the cytoplasm. Pictures were acquired 
on a Nikon Eclipse E600 with a Qimaging Retiga 1300 camera. The original magnification was X400.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Time-dependent effect of protein phosphatase 1/2A inhibition with okadaic acid on oocyte maturation Figure 7
Time-dependent effect of protein phosphatase 1/2A inhibition with okadaic acid on oocyte maturation. COC 
were cultured in okadaic acid-supplemented medium for different times followed by culture in inhibitor-free medium for up to 
a total of 12 (A) or 24 (B) hours of IVM; nuclear status was then assessed. Each column represents the mean percentages of 
oocytes in GV arrest (open bars), intermediate stage (grey bars) and mature stage (closed bars) ± SEM of at least three repli-
cates. The mean percentage of oocytes that displayed condensed scattered chromatin is presented (hatched bars) and is 
included in the intermediate stage percentage. The number of oocytes per treatment is indicated under each bar. Statistical 
analysis by ANOVA showed that the treatments had significant effects (P < 0.0001). Asterisks indicate significant differences (P 
< 0.01) from control according to the Bonferroni post hoc test.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
Page 12 of 18
(page number not for citation purposes)
nized GVBD oocytes would be needed. In the rat, a clear
increase of PDE3A activity occurs 30 minutes prior to
GVBD [21]. In the pig, the present study shows a peak in
cAMP-PDE3 activity 8 hours before GVBD and a loss of
the capacity of a PDE3-specific inhibitor to prevent the
resumption of meiosis 3 hours before GVBD. Control of
oocyte PDE activity has been reported in Xenopus, where
microinjection of constitutively active PKB has been
shown to increase activity and the GVBD rate [30]. Impli-
cation of PKB in the modulation of PDE activity remains
a possible mechanism for the resumption of meiosis.
From the 6 putative PKA and PKB serine phosphorylation
sites in the N-terminus of the murine PDE3A protein
sequence (NM_018779.1) described by Shitzukawa and
coworkers [11], 5 are present in rat (NM_017337.1), pig
(NM_213736.1) and human (NM_000921.3). In the
other gene of the same family, PDE3B, at least two of these
sites are conserved between rodents and human, and ser-
ine-302 is reportedly targeted by PKA and PKB in vitro
[31,32]. PDE3 has also been reported to be activated by
partially purified MAPK and PKB in rat hepatocytes [33].
PKB activation prior to GVBD has never been shown in
pig oocytes.
Because cAMP is probably involved in controlling re-entry
into the cell cycle in oocytes, the next step was to investi-
gate the role of cAMP in meiotic progression. It was con-
firmed that OA treatment overcame PDE3-specific
inhibition, suggesting that PP1/2A inhibition activates
signalling molecules downstream of cAMP-PDE3 in the
pig oocyte (figure 5B). This hypothesis is supported by
previous reports showing that IBMX-arrested or milrinone
(PDE3 inhibitor)-arrested mouse oocytes resume meiosis
when PP1/2A is inhibited with OA [25,34]. In the latter
study, PDE3 inhibition of OA-treated oocytes delayed
GVBD and reduced MPF activation [34]. Interestingly,
when using a spontaneous denuded oocyte maturation
model, PDE3 inhibition of 3 hours OA-treated oocytes
result in higher rates of intermediate stage oocyte com-
pared to OA-treated oocytes alone after 48 hours of IVM
(data not shown). These results support our findings,
showing that PDE3 inhibition affects meiotic progression
Effects of specific PDE3 inhibition on maturation of OA-treated oocytes Figure 8
Effects of specific PDE3 inhibition on maturation of OA-treated oocytes. COC were cultured in okadaic acid (2 
μM)-supplemented medium for 3 hours followed by culture in either inhibitor-free or cilostamide (20 μM)-supplemented 
medium for up to 24 hours of IVM. The nuclear status of the oocytes was then assessed. Each column represents the mean 
percentages of oocytes in GV arrest (open bars), intermediate stage (grey bars) and mature stage (closed bars) ± SEM of at 
least three replicates. The number of oocytes per treatment is indicated under each bar. Statistical analysis by ANOVA showed 
that the treatments had significant effects (P < 0.0001). Different letters indicate significant differences (P < 0.05) according to 
the Bonferroni post hoc test.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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Effects of specific PDE3 inhibition on maturation of OA-treated oocytes over 48 hours of IVM Figure 9
Effects of specific PDE3 inhibition on maturation of OA-treated oocytes over 48 hours of IVM. COC were initially 
cultured either in control conditions (A-C-E) or in okadaic acid (2 μM)-supplemented medium for 3 hours (B-D-F) Each group 
was cultured up to 12, 24, 36 and 48 hours of IVM alone (open symbols) or with cilostamide (20 μM, closed symbols). The 
nuclear status was then assessed in a sample of oocytes from each condition every 12 hours of IVM up to 48 hours. Results are 
presented as the mean percentages of oocytes in GV arrest (A-B), intermediate stage (C-D) and mature stage (E-F) ± SEM of at 
least three replicates. A total of 845 oocytes were used. Asterisks indicate significant differences between control and cilosta-
mide treated-oocytes or between okadaic acid and okadaic acid-cilostamide-treated oocytes according to the Bonferroni post 
hoc test. (*, P < 0.05; **, P < 0.01; ***, P < 0.001).BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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in OA-treated oocytes probably by delaying the decrease
of MPF activity that allows nuclear maturation to be com-
pleted (figures 8 and 9).
In vertebrates, the direct MPF regulators CDC25B and
Myt1 are candidate targets for PP1/2A [35]. In fission and
budding yeasts, a specific form of PP2A (PP2A-π) directly
protects centromeric cohesins from phosphorylation and
cleavage, preventing premature sister chromatin separa-
tion [36]. The cohesion of centromeres in sister chroma-
tids during metaphase I is of critical importance. In the
present study, fifty percent of oocytes remained at the
intermediate stage after 36 and 48 hours of IVM (figure
9F), suggesting that inhibition of PP1/2A with OA affects
the segregation machinery in a way that impairs homolo-
gous chromosome segregation without causing complete
meiotic spindle dissolution (figure 6). Similarly, transient
PP1/2A inhibition with a relatively high dose of OA (1.24
μM) compromised anaphase initiation and stopped mei-
osis in metaphase I in mouse oocytes, while low doses
(0.124 μM and 0.0124 μM) allowed normal meiosis to
continue until metaphase II arrest but with high rates of
chromosomal abnormalities [37]. In the present study,
the transient OA exposure approach allowed meiosis to
proceed to the mature stage. This approach was used suc-
cessfully in a previous study to reduce the incidence of
chromosome segregation defects and to improve the per-
centage of oocytes reaching metaphase II compared to the
continuously OA-treated group [38].
Wang and coworkers have shown that PKA inhibition is
one of the earliest events in progesterone-induced
resumption of meiosis in Xenopus oocytes [39]. Our
results suggest that effective PKA inhibition occurs late
after the start of IVM, since stimulation of the cAMP/PKA
pathway by PDE3 inhibition after 15 hours of IVM pre-
vents GVBD completely (figure 3A). PDE3 inhibition after
19 hours of IVM has no effect on the completion of mei-
osis (figure 4). In Xenopus, a similar experiment also
demonstrated that reactivating the cAMP/PKA pathway
after GVBD has no effect on the completion of meiosis
[39]. OA-stimulated oocytes react differently by being
delayed at an intermediate stage in the presence of the
PDE3 inhibitor (figures 8 and 9). The reason for this is
unclear; however, the capacity of the cumulus cells to
transfer cAMP to the oocyte could explain the effect. PDE3
inhibition, combined with insufficient cAMP transfer,
could prevent intracellular cAMP levels reaching a certain
threshold and compromise PKA activation. The level of
connexin 43 and its phosphorylation status have been
shown to vary in porcine cumulus cells during IVM [40].
Cyclic AMP has also been shown to inhibit proteasomal
proteolysis in rat sertoli cells, COS-1 African monkey kid-
ney cells and Y1 mouse adrenocortical tumour cells
[41,42]. Interestingly, porcine oocytes stop their nuclear
maturation in metaphase I when proteasomal degrada-
tion is inhibited [43]. It is possible that PDE3 inhibition
in OA-treated oocytes leads to a rise in cAMP level suffi-
cient to prevent proteasomal degradation and conse-
quently delays the transition from intermediate to mature
stage. The mechanism by which PDE3 inhibition main-
tains oocytes in the intermediate stage under OA-treated
conditions will require further investigation.
Conclusion
In summary, the present investigation has revealed new
insights into cAMP regulation during the resumption of
meiosis in porcine oocytes. It has demonstrated that
PDE3A is the major cAMP-degrading PDE activity and reg-
ulates meiotic resumption until 3 hours prior to GVBD. It
has also demonstrated that PDE3 inhibition affects mei-
otic progression in OA-treated oocytes. We suggest that
cAMP-PDE3A modulates meiotic resumption via a factor
located upstream of PP1/2A substrates. This study high-
lights a distinctive characteristic of porcine oocyte nuclear
maturation that makes it a valuable model for studying
cAMP modulation during maturation: the very long
latency period before the resumption of oocyte meiosis
and the late release of the control maintained by the
cAMP-PDE3 pathway over prophase arrest. Further exper-
iments will provide a better understanding of the mecha-
nisms involved in the control of PDE3A activity during
IVM and the fundamental role of the cAMP/PKA pathway
in the molecular mechanisms leading to meiotic matura-
tion.
Methods
Chemicals
Unless otherwise notified, all chemicals were purchased
from Sigma Chemical Co (St. Louis, MO, USA).
Ovary collection
Ovaries were collected as previously described [15].
Briefly, ovaries were recovered from a local slaughter-
house, placed in saline (0.9% NaCl) containing antibiot-
ics and antimycotics (100,000 IU/l penicillin G, 100 mg/
l streptomycin, 250 μg/l amphotericin B) and maintained
at 34°C. Upon arrival in the laboratory, they were rinsed
in saline containing antibiotics and antimycotics at 34°C.
PDE assay
COC were suspended in hypotonic buffer (Tris-HCl 20
mM, pH 7.4, ethylenedioxy-diethylene-dinitrilo-tetraace-
tic acid (EDTA) 1 mM, ethylene glycol-bis-(2-aminoe-
thyl)-N, N, N', N'-tetraacetic acid (EGTA) 0.2 mM, NaF 50
mM, benzamidine 50 mM, sodium pyrophosphate 10
mM, aprotinin 4 μg/ml, pepstatin 0.7 μg/ml, soybean
trypsin inhibitor 10 μg/ml, leupeptin 0.5 μg/ml and phe-
nylmethylsulfonyl fluoride 2 mM) and homogenized by 9
freezing-thawing cycles along with vortex agitation. In allBMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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experiments, the hypotonic buffer contained 0.5% Triton
X-100. Tris-HCl was purchased from Fisher Scientific Lim-
ited (Nepean, ON, Canada). The homogenate was centri-
fuged for 20 min at 14000 × g to obtain the supernatant.
PDE activity was assessed at 34°C in 200 μl final volume
with 1 μM cAMP as substrate following the method of
Thompson et al. [44] with minor modifications [21]; the
solution comprised 40 mM Tris-HCl pH 8.0, 10 mM
MgCl2, 5 mM 2-mercaptoethanol, 0.75 mg/ml BSA (Frac-
tion V), 1 μM cold cAMP and 15 nM [3H]cAMP (GE
Healthcare, Baie d'Urfé, QC, Canada) (1 × 105 cpm/tube;
30 Ci/mmol). Measurements were performed in the pres-
ence of PDE inhibitors: 3-isobutyl-methylxanthine
(IBMX) (1mM, non-specific), cilostamide (Cil) (10 μM,
PDE3-specific) and rolipram (Rol) (10 μM, PDE4-spe-
cific). Cilostamide and rolipram were purchased from
Biomol (Plymouth Meeting, PA, USA). To determine the
contributions of different PDEs to the overall PDE activ-
ity, the activity measured in the presence of the respective
inhibitors was subtracted from the total. Each enzyme
assay was performed in triplicate for each experiment and
each experiment was repeated at least three times.
RNA extraction and RT-PCR
RNA extractions were carried out using an "Absolutely
RNA Microprep Kit" from Stratagene (La Jolla, CA, USA)
according to the manufacturer's protocol. RNA samples
w e r e  e l u t e d  i n  1 5  μl followed by reverse transcription
using an "OmniScript RT Kit" from Qiagen (Valencia, CA,
USA) and poly (dT) from Ambion (Austin, TX, USA). To
each tube, a mixture containing 2 μl of Omniscript 5×
Buffer (Qiagen, Mississauga, ON, Canada), 2 μl of 50 μM
dNTPs (Qiagen), 0.25 μl of 40 U/μl RNASIN (Promega,
Madison, WI, USA) and 1 μl of Omniscript Reverse Tran-
scriptase (Qiagen) was added. The mixture was then incu-
bated at 42°C for 2 hours. The primer pairs were designed
on the basis of bovine β-actin (AY141970.1) and human
PDE3A sequences (NM_000921.2) and are described in
table 1. They were purchased from Integrated DNA Tech-
nologies (Skokie, IL, USA). PCR reactions were carried out
in a 50 μl reaction volume using Taq polymerase from
New England Biolabs (Ipswich, MA, USA). The following
cycling conditions were used for all amplifications: 2 min-
utes 95°C, [1 minute 95°C, 1 minute 60°C, 1 minute
72°C] 35 times, and 10 minutes 72°C. Additional ampli-
fications were performed on an equivalent amount of
RNA to exclude genomic DNA contamination. PCR prod-
ucts were visualized by 1% agarose gel electrophoresis and
ethidium bromide staining.
Culture of cumulus-oocyte complexes (COCs) and 
assessment of meiotic status
Media, COC collection, selection and culture conditions
were described previously [15]. Briefly, a group of 30 to 50
COCs were selected and washed three times with HEPES-
buffered Tyrode medium containing 0.01% (w/v) polyvi-
nyl alcohol (PVA-HEPES) [45]. They were then cultured in
Nunclon™Δ 4-well dishes in 500 μl standard porcine IVM
culture medium, namely; BSA-free NCSU 23 medium [46]
containing 25 μM beta-mercaptoethanol (Bio Rad), 0.1
mg/ml cysteine, 10% (v/v) filtered porcine follicular fluid
and gonadotropin supplements at final concentrations of
2.5 IU/ml hCG (Ayerst Laboratories, Inc., Philadelphia,
PA, USA) and 2.5 IU/ml PMSG (Intervet, Whitby, ON,
Canada). Wells were covered with a mineral oil overlay.
Oocyte nuclear status was assessed using aceto-orcein as
previously described [15]. Oocyte nuclear maturation sta-
tus was classified as (1) GV stage oocyte when displaying
a germinal vesicle, (2) intermediate stage oocyte when
displaying germinal vesicle breakdown and condensed
chromatin or metaphase I organised chromatin, or (3)
mature stage oocyte when displaying anaphase I, telo-
phase I or metaphase II DNA configuration.
Experimental design
Contributions of different cAMP-degrading PDEs in the 
oocyte
In experiment 1, cAMP-degrading PDE activity was meas-
ured in the COC after recovery from the ovary, and the
individual contributions of the PDE3 and PDE4 isoen-
zymes were determined by the method described above.
To evaluate the distribution of PDE activity further, over-
all PDE activity and specific PDE3 activity were measured
in both COC and denuded oocytes. The results are pre-
sented as total and cilostamide-sensitive (PDE3) cAMP-
PDE activities. The presence of PDE3A mRNA was con-
firmed in the oocyte by RT-PCR amplification. Total RNA
was extracted and reverse transcribed from 100 denuded
oocytes. The resulting cDNA was used as template for
PDE3A PCR amplification. To verify the absence of con-
taminating genomic DNA from the RNA extract, PCR was
also performed directly on the RNA sample (data not
Table 1: Primers used for PCR reactions. The sequences of the primers used to amplify PDE3A and β-actin mRNA in the oocyte cDNA 
are shown, along with the expected sizes of the PCR products. Sasseville et al. 2006.
Gene Primer Primer sequences PCR product expected size (bp)
β-actin β-actin-F 5'-ATCCTGACCCTCAAGTACCCCAT-3' 242
β-actin-R 5'-TACTCCTGCTTGCTGATCCACAT-3'
PDE3A PDE3A-F 5'-GAACAGATGACACTGCTCAAGTT-3' 180
PDE3A-R 5'-GAGCAAGAATTGGTTTGTCCAG-3'BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
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shown). In experiment 2, PDE activity was measured in
the oocyte during IVM. After the IVM culture, COC were
stripped of their cumulus cells and the denuded oocytes
were rinsed in PVA-HEPES and snap-frozen in liquid
nitrogen. Cyclic AMP-degrading PDE activity was meas-
ured and total, IBMX-sensitive and cilostamide-sensitive
PDE activities are presented.
Time-dependent ability of specific PDE3 inhibition to 
maintain COC in meiotic arrest
In experiment 3, oocytes were cultured and meiotic matu-
ration was monitored every 6 hours to evaluate the
moment of resumption of meiosis. On the basis of previ-
ous studies, it is known that inhibiting PDE3 with cilosta-
mide at the beginning of IVM prevents GVBD [15]. To
determine the cAMP-sensitive period during which
oocytes were not irrevocably committed to resuming mei-
osis and could still be maintained at the GV stage, addi-
tion of cilostamide to the IVM medium was postponed
and nuclear status was assessed after 24 hours of IVM. In
experiment 4, to determine whether PDE3 inhibition
affected meiotic progression, COC were kept in normal
IVM conditions for the first 19 hours. Cilostamide was
added to half of them and the other half were maintained
under normal IVM conditions. The oocytes were denuded
and were fixed for assessment of nuclear maturation after
19, 24, 30, 36 and 48 hours of IVM. Oocyte nuclear mat-
uration status was classified as described above.
Effects of short OA exposure in the presence of PDE3 
inhibition on oocyte nuclear maturation
In experiment 5, oocytes were continuously exposed to
OA during IVM in order to study the effect of PDE3 inhi-
bition on the resumption of meiosis in premature-GVBD
oocytes treated with OA. COC were cultured in OA-sup-
plemented media for 6 and 12 hours and the nuclear sta-
tus of the oocytes was evaluated. The effect of PDE3-
specific inhibition on the resumption of meiosis was
assessed by exposing OA-treated oocytes to cilostamide
for 24 hours of IVM. The results are reported as mean per-
centages of arrested, intermediate or mature stage oocytes.
In experiment 6, to study the effect of PDE3 inhibition on
the progression of meiosis past GVBD, three conditions of
transient OA exposure were tested and compared to con-
trol conditions: (1) 1 hour OA-exposure followed by 11 or
23 hours of normal IVM; (2) 3 hours OA exposure fol-
lowed by 9 or 21 hours of normal IVM; and (3) continu-
ous OA exposure for 12 or 24 hours. The percentages of
arrested, intermediate and mature stage oocytes, as
described for experiment 4, are reported here after 12
hours and 24 hours of IVM. The percentages of oocytes
displaying a scattered condensed chromatin configuration
were also evaluated and are included in the intermediate
stage percentage. Representative pictures of normal met-
aphase I and OA-treated condensed scattered chromatin
oocytes are shown. In experiment 7, to assess the effect of
PDE3 inhibition on 3 hours OA-treated COC, the COC
were treated with OA for three hours followed either by
normal culture conditions or treatment with the PDE3
inhibitor cilostamide. Oocytes were collected after 24
hours of IVM for assessment of nuclear maturation. The
percentages of oocytes in arrested, intermediate or mature
stages after IVM are reported here. In experiment 8, the
effects of PDE3 inhibition on OA-treated COC were stud-
ied throughout the IVM period. Oocytes were exposed for
3 hours to OA followed by PDE3 inhibition up to 48
hours. Samples were fixed at 12, 24, 36 or 48 hours for
assessment of nuclear status.
Statistical analyses
Statistical analyses were performed using Prism 4.00
GraphPad for Windows (GraphPad Software, San Diego,
CA, USA). The onsets of 50% GVBD and of 50% cilosta-
mide efficacy were calculated using non-linear regression
with a sigmoidal dose-response equation. Statistical sig-
nificances of PDE activity measurements and nuclear mat-
uration status were assessed using one-way ANOVA
analysis and the Bonferroni multiple comparison post-hoc
test to identify individual differences between means.
Probabilities of less then 0.05 were considered statistically
significant.
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phatase 1/2A; Cil: cilostamide; Rol: rolipram.
Authors' contributions
All authors participated in the design of the study. MS car-
ried out PDE activity measurements and oocyte matura-
tion studies and drafted the manuscript. MS, NC, and CG
collected the oocytes. NC and CG performed the PDE
assays. FJR conceived the study, participated to its design
and helped in the writing of the manuscript. All authors
read, modified and approved the final manuscript.
Acknowledgements
Thanks to Dr Mario Mayes for a critical review of the manuscript. Special 
thanks to Isabelle Laflamme for professional technical assistance. We also 
thank Richard Prince and O'Neil Fecteau for collecting ovaries at the 
slaughterhouse. MS is supported by a NSERC and FQRNT PhD fellowship. 
This project was supported by the Canadian Institutes for Health Research 
in the Program for Oocyte Health.BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
Page 17 of 18
(page number not for citation purposes)
References
1. Mehlmann LM: Stops and starts in mammalian oocytes: recent
advances in understanding the regulation of meiotic arrest
and oocyte maturation.  Reproduction 2005, 130(6):791-799.
2. Hinckley M, Vaccari S, Horner K, Chen R, Conti M: The G-protein-
coupled receptors GPR3 and GPR12 are involved in cAMP
signaling and maintenance of meiotic arrest in rodent
oocytes.  Dev Biol 2005, 287(2):249-261.
3. Cho WK, Stern S, Biggers JD: Inhibitory effect of dibutyryl cAMP
on mouse oocyte maturation in vitro.  J Exp Zool 1974,
187(3):383-386.
4. Rice C, McGaughey RW: Effect of testosterone and dibutyryl
cAMP on the spontaneous maturation of pig oocytes.  J Reprod
Fertil 1981, 62(1):245-256.
5. Bilodeau S, Fortier MA, Sirard MA: Effect of adenylate cyclase
stimulation on meiotic resumption and cyclic AMP content
of zona-free and cumulus-enclosed bovine oocytes in vitro.  J
Reprod Fertil 1993, 97(1):5-11.
6. Urner F, Herrmann WL, Baulieu EE, Schorderet-Slatkine S: Inhibi-
tion of denuded mouse oocyte meiotic maturation by for-
skolin, an activator of adenylate cyclase.  Endocrinology 1983,
113(3):1170-1172.
7. Aktas H, Wheeler MB, First NL, Leibfried-Rutledge ML: Mainte-
nance of meiotic arrest by increasing [cAMP]i may have
physiological relevance in bovine oocytes.  J Reprod Fertil 1995,
105(2):237-245.
8. Matten W, Daar I, Vande Woude GF: Protein kinase A acts at
multiple points to inhibit Xenopus oocyte maturation.  Mol
Cell Biol 1994, 14(7):4419-4426.
9. Han SJ, Chen R, Paronetto MP, Conti M: Wee1B is an oocyte-spe-
cific kinase involved in the control of meiotic arrest in the
mouse.  Curr Biol 2005, 15(18):1670-1676.
10. Conti M, Andersen CB, Richard F, Mehats C, Chun SY, Horner K, Jin
C, Tsafriri A: Role of cyclic nucleotide signaling in oocyte mat-
uration.  Mol Cell Endocrinol 2002, 187(1-2):153-159.
11. Shitsukawa K, Andersen CB, Richard FJ, Horner AK, Wiersma A, van
Duin M, Conti M: Cloning and characterization of the cyclic
guanosine monophosphate-inhibited phosphodiesterase
PDE3A expressed in mouse oocyte.  Biol Reprod 2001,
65(1):188-196.
12. Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M: Oocyte matura-
tion involves compartmentalization and opposing changes of
cAMP levels in follicular somatic and germ cells: studies
using selective phosphodiesterase inhibitors.  Dev Biol 1996,
178(2):393-402.
13. Mayes MA, Sirard MA: Effect of type 3 and type 4 phosphodi-
esterase inhibitors on the maintenance of bovine oocytes in
meiotic arrest.  Biol Reprod 2002, 66(1):180-184.
14. Thomas RE, Armstrong DT, Gilchrist RB: Differential effects of
specific phosphodiesterase isoenzyme inhibitors on bovine
oocyte meiotic maturation.  Dev Biol 2002, 244(2):215-225.
15. Laforest MF, Pouliot E, Gueguen L, Richard FJ: Fundamental signif-
icance of specific phosphodiesterases in the control of spon-
taneous meiotic resumption in porcine oocytes.  Mol Reprod
Dev 2005, 70(3):361-372.
16. Grupen CG, Fung M, Armstrong DT: Effects of milrinone and
butyrolactone-I on porcine oocyte meiotic progression and
developmental competence.  Reprod Fertil Dev 2006,
18(3):309-317.
17. Jensen JT, Schwinof KM, Zelinski-Wooten MB, Conti M, DePaolo LV,
Stouffer RL: Phosphodiesterase 3 inhibitors selectively block
the spontaneous resumption of meiosis by macaque oocytes
in vitro.  Hum Reprod 2002, 17(8):2079-2084.
18. Nogueira D, Albano C, Adriaenssens T, Cortvrindt R, Bourgain C,
Devroey P, Smitz J: Human oocytes reversibly arrested in
prophase I by phosphodiesterase type 3 inhibitor in vitro.  Biol
Reprod 2003, 69(3):1042-1052.
19. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M: Impaired growth
and fertility of cAMP-specific phosphodiesterase PDE4D-
deficient mice.  Proc Natl Acad Sci U S A 1999, 96(21):11998-12003.
20. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S,
Nedachi T, Jin C, Conti M, Manganiello V: Cyclic nucleotide phos-
phodiesterase 3A-deficient mice as a model of female infer-
tility.  J Clin Invest 2004, 114(2):196-205.
21. Richard FJ, Tsafriri A, Conti M: Role of phosphodiesterase type
3A in rat oocyte maturation.  Biol Reprod 2001, 65(5):1444-1451.
22. Brunet S, Maro B: Cytoskeleton and cell cycle control during
meiotic maturation of the mouse oocyte: integrating time
and space.  Reproduction 2005, 130(6):801-811.
23. Fan HY, Sun QY: Involvement of mitogen-activated protein
kinase cascade during oocyte maturation and fertilization in
mammals.  Biol Reprod 2004, 70(3):535-547.
24. Sugiura K, Naito K, Endo T, Tojo H: Study of germinal vesicle
requirement for the normal kinetics of maturation/M-phase-
promoting factor activity during porcine oocyte maturation.
Biol Reprod 2006, 74(3):593-600.
25. Gavin AC, Vassalli JD, Cavadore JC, Schorderet-Slatkine S: Okadaic
acid and p13suc1 modulate the reinitiation of meiosis in
mouse oocytes.  Mol Reprod Dev 1992, 33(3):287-296.
26. Liang CG, Huo LJ, Zhong ZS, Chen DY, Schatten H, Sun QY: Cyclic
adenosine 3',5'-monophosphate-dependent activation of
mitogen-activated protein kinase in cumulus cells is essential
for germinal vesicle breakdown of porcine cumulus-enclosed
oocytes.  Endocrinology 2005, 146(10):4437-4444.
27. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC,
Bondy CA: Distinctive anatomical patterns of gene expression
for cGMP-inhibited cyclic nucleotide phosphodiesterases.  J
Clin Invest 1995, 95(4):1528-1538.
28. Shimada M, Ito J, Yamashita Y, Okazaki T, Isobe N: Phosphatidyli-
nositol 3-kinase in cumulus cells is responsible for both sup-
pression of spontaneous maturation and induction of
gonadotropin-stimulated maturation of porcine oocytes.  J
Endocrinol 2003, 179(1):25-34.
29. Edry I, Sela-Abramovich S, Dekel N: Meiotic arrest of oocytes
depends on cell-to-cell communication in the ovarian follicle.
Mol Cell Endocrinol 2006.
30. Andersen CB, Roth RA, Conti M: Protein kinase B/Akt induces
resumption of meiosis in Xenopus oocytes.  J Biol Chem 1998,
273(30):18705-18708.
31. Degerman E, Landstr inverted question markm TR, Wijkander J,
Holst LS, Ahmad F, Belfrage P, Manganiello V: Phosphorylation and
activation of hormone-sensitive adipocyte phosphodieste-
rase type 3B.  Methods 1998, 14(1):43-53.
32. Wijkander J, Landstrom TR, Manganiello V, Belfrage P, Degerman E:
Insulin-induced phosphorylation and activation of phos-
phodiesterase 3B in rat adipocytes: possible role for protein
kinase B but not mitogen-activated protein kinase or p70 S6
kinase.  Endocrinology 1998, 139(1):219-227.
33. Watanabe T, Satoo H, Kohara K, Takami R, Motoyashiki T, Morita T,
Ueki H: Orthovanadate stimulates cAMP phosphodiesterase
3 activity in isolated rat hepatocytes through mitogen-acti-
vated protein kinase activation dependent on cAMP-depend-
ent protein kinase.  Biol Pharm Bull 2004, 27(6):789-796.
34. Kalous J, Solc P, Baran V, Kubelka M, Schultz RM, Motlik J: PKB/AKT
is involved in resumption of meiosis in mouse oocytes.  Biol
Cell 2006, 98(2):111-123.
35. Jessus C, Ozon R: How does Xenopus oocyte acquire its com-
petence to undergo meiotic maturation?  Biol Cell 2004,
96(3):187-192.
36. Riedel CG, Katis VL, Katou Y, Mori S, Itoh T, Helmhart W, Galova M,
Petronczki M, Gregan J, Cetin B, Mudrak I, Ogris E, Mechtler K, Pel-
letier L, Buchholz F, Shirahige K, Nasmyth K: Protein phosphatase
2A protects centromeric sister chromatid cohesion during
meiosis I.  Nature 2006, 441(7089):53-61.
37. Mailhes JB, Hilliard C, Fuseler JW, London SN: Okadaic acid, an
inhibitor of protein phosphatase 1 and 2A, induces prema-
ture separation of sister chromatids during meiosis I and
aneuploidy in mouse oocytes in vitro.  Chromosome Res 2003,
11(6):619-631.
38. Sun QY, Wu GM, Lai L, Bonk A, Cabot R, Park KW, Day BN, Prather
RS, Schatten H: Regulation of mitogen-activated protein
kinase phosphorylation, microtubule organization, chroma-
tin behavior, and cell cycle progression by protein phos-
phatases during pig oocyte maturation and fertilization in
vitro.  Biol Reprod 2002, 66(3):580-588.
39. Wang J, Cao WL, Liu XJ: Protein kinase A(PKA)-restrictive and
PKA-permissive phases of oocyte maturation.  Cell Cycle 2006,
5(2):213-217.
40. Shimada M, Maeda T, Terada T: Dynamic changes of connexin-
43, gap junctional protein, in outer layers of cumulus cells
are regulated by PKC and PI 3-kinase during meioticPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Developmental Biology 2006, 6:47 http://www.biomedcentral.com/1471-213X/6/47
Page 18 of 18
(page number not for citation purposes)
resumption in porcine oocytes.  Biol Reprod 2001,
64(4):1255-1263.
41. Hoang T, Fenne IS, Cook C, Borud B, Bakke M, Lien EA, Mellgren G:
cAMP-dependent protein kinase regulates ubiquitin-protea-
some-mediated degradation and subcellular localization of
the nuclear receptor coactivator GRIP1.  J Biol Chem 2004,
279(47):49120-49130.
42. Lui WY, Lee WM: cAMP perturbs inter-Sertoli tight junction
permeability barrier in vitro via its effect on proteasome-
sensitive ubiquitination of occludin.  J Cell Physiol 2005,
203(3):564-572.
43. Chmelikova E, Sedmikova M, Rajmon R, Petr J, Svestkova D, Jilek F:
Effect of proteasome inhibitor MG132 on in vitro maturation
of pig oocytes.  Zygote 2004, 12(2):157-162.
44. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ: Assay of cyclic
nucleotide phosphodiesterase and resolution of multiple
molecular forms of the enzyme.  Adv Cyclic Nucleotide Res 1979,
10:69-92.
45. Funahashi H, Cantley TC, Day BN: Synchronization of meiosis in
porcine oocytes by exposure to dibutyryl cyclic adenosine
monophosphate improves developmental competence fol-
lowing in vitro fertilization.  Biol Reprod 1997, 57(1):49-53.
46. Petters RM, Wells KD: Culture of pig embryos.  J Reprod Fertil
Suppl 1993, 48:61-73.